Paper Details

  1. Home
  2. Paper Details

Differential body composition effects of protease inhibitors recommended for initial treatment of HIV infection: a randomized clinical trial.

Author: , BernardinoJose I, CartonJose A, CurranAdrià, DeulofeuRamon, DomingoPere, FerrerElena, GatellJose M, Gonzalez-CordonAna, GutierrezFelix, MartinezEsteban, MurillasJavier, NegredoEugenia, PeraireJoaquim, PerezIgnacio, PichJudit, PodzamczerDaniel, PortillaJoaquin, RiberaEsteban, SantosIgnacio

Clinical Trial, Phase IVPost-marketing surveillance. Monitors long-term safety/efficacy after approval.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Atazanavir/ritonavir led to higher triglycerides and more total and subcutaneous fat than darunavir/ritonavir. Both regimens were effective and had similar side effects.
Paper Details　
Original Abstract of the Article :
BACKGROUND: It is unclear whether metabolic or body composition effects differ between protease inhibitor-based regimens recommended for initial treatment of human immunodeficiency virus (HIV) infection. METHODS: ATADAR is a phase 4, open-label, multicenter, randomized clinical trial. Stable antire...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1093/cid/ciu898

データ提供：米国国立医学図書館（NLM）

Exploring the Metabolic Landscape of HIV Treatment

This research delves into the metabolic and body composition effects of two protease inhibitor-based regimens used for initial treatment of HIV infection. The study investigates the long-term effects of atazanavir/ritonavir and darunavir/ritonavir on body fat distribution, lipid profiles, and insulin resistance. The authors' findings highlight potential differences in metabolic profiles between these two treatment regimens.

Navigating the Metabolic Desert of HIV Treatment

The study explores the complex metabolic effects of different HIV treatment regimens. The authors provide a detailed comparison of atazanavir/ritonavir and darunavir/ritonavir, highlighting the potential impact on body composition and insulin resistance. This research underscores the importance of personalized treatment approaches to minimize metabolic side effects in HIV patients.

Finding Balance in the Desert of HIV Treatment

This research underscores the importance of understanding the metabolic effects of HIV treatment regimens. The study's findings highlight the potential differences in metabolic profiles between atazanavir/ritonavir and darunavir/ritonavir. This knowledge can guide clinicians in tailoring treatment plans to minimize metabolic side effects and improve long-term outcomes for HIV-infected individuals. Like a camel navigating the desert, those living with HIV must find balance and adapt to the changing landscape of their health.

Dr. Camel's Conclusion

This research provides valuable insights into the metabolic and body composition effects of different protease inhibitor-based regimens used in HIV treatment. The study highlights the importance of individualized treatment approaches to manage metabolic side effects and optimize patient outcomes. This research is a reminder that the journey through HIV treatment requires careful navigation and adaptation, just as a camel journeys across the desert, seeking out the best paths to reach its destination.
Date :
  1. Date Completed 2016-05-02
  2. Date Revised 2022-03-30
Further Info :

Pubmed ID

25389256

DOI: Digital Object Identifier

10.1093/cid/ciu898

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.